Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

Massimiliano Fabbiani; Simona Di Giambenedetto; E Quiros Roldan; A Latini; V Vullo; A Antinori; A Castagna; G Orofino; D Francisci; E Grilli; G Madeddu; Pierfrancesco Grima; S Rusconi; B Del Pin; Annalisa Mondi; Alberto Borghetti; E Focà; Manuela Colafigli; Andrea De Luca; Roberto Cauda

doi:10.7448/IAS.17.4.19808

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

Massimiliano Fabbiani, Simona Di Giambenedetto, E Quiros Roldan, A Latini, V Vullo, A Antinori, A Castagna, G Orofino, D Francisci, E Grilli, G Madeddu, Pierfrancesco Grima, S Rusconi, B Del Pin, Annalisa Mondi, Alberto Borghetti, E Focà, Manuela Colafigli, Andrea De Luca, Roberto Cauda

Research output: Contribution to journal › Conference article › peer-review

Abstract

We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.

Original language	English
Pages (from-to)	19808-19808
Number of pages	1
Journal	Journal of the International AIDS Society
Volume	17
DOIs	https://doi.org/10.7448/IAS.17.4.19808
Publication status	Published - 2014
Event	HIV Drug Therapy Glasgow Congress 2014 - Glasgow Duration: 2 Nov 2014 → 6 Nov 2014

Keywords

HIV
simplification

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7448/IAS.17.4.19808

Cite this

Fabbiani, M., Di Giambenedetto, S., Quiros Roldan, E., Latini, A., Vullo, V., Antinori, A., Castagna, A., Orofino, G., Francisci, D., Grilli, E., Madeddu, G., Grima, P., Rusconi, S., Del Pin, B., Mondi, A., Borghetti, A., Focà, E., Colafigli, M., De Luca, A., & Cauda, R. (2014). Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. Journal of the International AIDS Society, 17, 19808-19808. https://doi.org/10.7448/IAS.17.4.19808

@article{81d2f1a824da4aa3919bf22a4921b619,

title = "Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial",

abstract = "We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.",

keywords = "HIV, simplification, HIV, simplification",

author = "Massimiliano Fabbiani and {Di Giambenedetto}, Simona and {Quiros Roldan}, E and A Latini and V Vullo and A Antinori and A Castagna and G Orofino and D Francisci and E Grilli and G Madeddu and Pierfrancesco Grima and S Rusconi and {Del Pin}, B and Annalisa Mondi and Alberto Borghetti and E Foc{\`a} and Manuela Colafigli and {De Luca}, Andrea and Roberto Cauda",

year = "2014",

doi = "10.7448/IAS.17.4.19808",

language = "English",

volume = "17",

pages = "19808--19808",

journal = "Journal of the International AIDS Society",

issn = "1758-2652",

publisher = "London: BioMed Central",

note = "HIV Drug Therapy Glasgow Congress 2014 ; Conference date: 02-11-2014 Through 06-11-2014",

}

Fabbiani, M, Di Giambenedetto, S, Quiros Roldan, E, Latini, A, Vullo, V, Antinori, A, Castagna, A, Orofino, G, Francisci, D, Grilli, E, Madeddu, G, Grima, P, Rusconi, S, Del Pin, B, Mondi, A, Borghetti, A, Focà, E, Colafigli, M, De Luca, A & Cauda, R 2014, 'Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial', Journal of the International AIDS Society, vol. 17, pp. 19808-19808. https://doi.org/10.7448/IAS.17.4.19808

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial. / Fabbiani, Massimiliano; Di Giambenedetto, Simona; Quiros Roldan, E et al.
In: Journal of the International AIDS Society, Vol. 17, 2014, p. 19808-19808.

Research output: Contribution to journal › Conference article › peer-review

TY - JOUR

T1 - Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

AU - Fabbiani, Massimiliano

AU - Di Giambenedetto, Simona

AU - Quiros Roldan, E

AU - Latini, A

AU - Vullo, V

AU - Antinori, A

AU - Castagna, A

AU - Orofino, G

AU - Francisci, D

AU - Grilli, E

AU - Madeddu, G

AU - Grima, Pierfrancesco

AU - Rusconi, S

AU - Del Pin, B

AU - Mondi, Annalisa

AU - Borghetti, Alberto

AU - Focà, E

AU - Colafigli, Manuela

AU - De Luca, Andrea

AU - Cauda, Roberto

PY - 2014

Y1 - 2014

N2 - We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.

AB - We report interim 24-weeks efficacy data of ATLAS-M trial, a phase IV, multicentre, open-label, randomized study designed to show 48-weeks, non-inferior efficacy (margin of -12%) of treatment simplification to atazanavir/ritonavir (ATV/r)+lamivudine (3TC) versus maintaining 3-drugs ATV/r-based cART.

KW - HIV

KW - simplification

KW - HIV

KW - simplification

UR - http://hdl.handle.net/10807/61166

U2 - 10.7448/IAS.17.4.19808

DO - 10.7448/IAS.17.4.19808

M3 - Conference article

SN - 1758-2652

VL - 17

SP - 19808

EP - 19808

JO - Journal of the International AIDS Society

JF - Journal of the International AIDS Society

T2 - HIV Drug Therapy Glasgow Congress 2014

Y2 - 2 November 2014 through 6 November 2014

ER -

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this